Clinical InvestigationPooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
Under an Elsevier user license
open archive
Keywords
diabetic nephropathy
glomerular filtration rate
kidney diseases
SGLT2 inhibition
Cited by (0)
see commentary on page 22
© 2017 International Society of Nephrology. Published by Elsevier Inc.